Jagsonpal Pharma to acquire 85% stake in Aequitas Healthcare for ₹20.8 Cr
Jagsonpal Pharmaceuticals will acquire an 85% stake in Aequitas Healthcare for ₹20.8 crore in cash. The deal is expected to close by July 15, 2026. Aequitas reported ₹53.31 crore revenue in FY26 and focuses on hospital sales. This acquisition aims to strengthen Jagsonpal's presence in the hospital segment.
The acquisition of a controlling stake in another company is a significant corporate action that will likely impact Jagsonpal's market position and future financial performance.
The acquisition is a strategic move expected to enhance Jagsonpal's market presence and revenue streams, indicating a positive outlook for the company's growth.
Jagsonpal Pharmaceuticals Limited has entered into a Share Purchase Agreement (SPA) to acquire an 85% stake in Aequitas Healthcare Private Limited. Aequitas Healthcare is engaged in the sale and distribution of pharmaceutical products to hospitals.
The proposed acquisition is strategic, aligning with Jagsonpal's objective to gain access to the hospital channel and institutional doctor network, thereby reducing the time required for organic relationship building. The transaction is expected to be completed by July 15, 2026, and is funded through internal accruals.
For the financial year 2025-26, Aequitas Healthcare reported revenues of ₹53.31 crore. The total cash consideration for the 85% stake is ₹20.8 crore. The current directors of Aequitas will retain the remaining 15% stake and continue their association with the business.
Manish Gupta, Managing Director of Jagsonpal, stated that the acquisition provides a ready platform for a meaningful presence in the hospital segment, which contributes approximately 10% of the pharmaceutical industry's sales and is growing faster. He believes Jagsonpal's established brands will benefit from Aequitas's strong institutional relationships.
Amrut Medhekar, Chief Operating Officer of Jagsonpal, described the transaction as a transformative pivot from a legacy retail prescription player to an omnichannel specialty healthcare business. Shailesh Kamat, Director and largest shareholder at Aequitas, expressed pleasure in associating with Jagsonpal, citing their proven track record in building healthcare brands.
What to do with a filing like this
Jagsonpal Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Jagsonpal Pharmaceuticals Limited. Read the original for the full detail.